Crinetics Pharmaceuticals CRNX License — Milestone revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:MilestoneRevenue.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
Pursuant to the SKK License, we received a $13.0 million nonrefundable upfront payment and would be eligible to receive up to $25.5 million in development, regulatory, and commercial milestone payments, as well as sales-based royalties upon market approval in Japan. In 2024, we updated the estimated transaction price to $14.0 million following the achievement of a development milestone. In April 2026, we achieved $1.5 million of development milestones related to SKK's NDA submission in Japan for paltusotine for the treatment of acromegaly.
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's license — milestone revenue?
- Crinetics Pharmaceuticals (CRNX) reported license — milestone revenue of $1.5M in Q2 2026.
- What does license — milestone revenue mean?
- Revenue recognized upon the successful achievement of specific, contractually defined events such as regulatory approvals or clinical trial results. This metric tracks the realization of variable consideration within licensing agreements. It is a vital indicator of the company's ability to successfully advance its pipeline and convert research progress into financial results.
Ask your AI about Crinetics Pharmaceuticals's license — milestone revenue.
Connect your AI assistant and compare it to peers, right in your chat.
